Search
forLearn
5 / 801 resultslearn He Shou Wu
learn SCUBE3
a signaling molecule from dermal papilla cells being actively researched
learn Snapdragon
learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
Research
5 / 1000+ results
research A clinical investigation using reflectance confocal microscopy to evaluate the add-on efficacy of the Shumin treatment instrument combined with doxycycline for rosacea
The Shumin device with doxycycline is more effective for rosacea than red light therapy.
research Regulation of Mitochondrial Oxidative Metabolism by Tumor Suppressor FLCN
The tumor suppressor gene FLCN affects mitochondrial function and energy use in cells.
research In vitro biomimetic platforms featuring a perfusion system and 3D spheroid culture promote the construction of tissue-engineered corneal endothelial layers
Using a perfusion system and 3D spheroid culture improves the growth of corneal cell layers for tissue engineering.
research Composite biomaterials in immunomodulation: A new era in targeted therapy
Composite biomaterials can precisely control immune responses for better disease treatment.
research Platelet Concentrates in Regenerative Medicine: A Comparative Review of Platelet-Rich Plasma, Platelet-Rich Fibrin, and Concentrated Growth Factors
PRF and CGF are becoming more popular than PRP in regenerative medicine due to their simplicity and lack of additives.
Community Join
5 / 1000+ resultscommunity The Chinese version of Stemson Therapeutics (Hair Multiplication) is here. It is called Yunce Medical.
Yunce Medical, a Chinese company, is developing hair multiplication technology similar to Stemson Therapeutics, with potential for quicker availability due to favorable regulations. Users express skepticism and hope for future advancements in hair loss treatments.
community HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
community Shiseido RCH-01
Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.
community SUBE3 for sale in the gray market?
SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.
community HMI-115: What We Know So Far. HMI-115 (also known as BAY1158061) is a new pharmaceutical drug developed by a biopharmaceutical company called Bioinvent and licensed by Bayer
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.